Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 1/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.50 |
| ▸ | PTGES | O14684 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.49 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | AGXT | P21549 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13859664 | 0.83 | PYCR1 (0.54) | PYCR1TAAR1PTGESSIGMAR1RIPK1 | |
| SCHEMBL17266739 | 0.78 | TAAR1 (0.47) | TAAR1PTGESIDO1NR3C1MEN1 | |
| SCHEMBL578605 | 0.78 | TAAR1 (0.66) | PYCR1TAAR1PTGESSIGMAR1RIPK1 | |
| SCHEMBL13859022 | 0.77 | TAAR1 (0.50) | TAAR1RIPK1IDO1AGXTMEN1 | |
| SCHEMBL16399455 | 0.77 | PYCR1 (0.65) | PYCR1TAAR1PTGESSIGMAR1RIPK1 | |
| SCHEMBL1639815 | 0.75 | HDAC1 (0.55) | PYCR1TAAR1MAOBHDAC1HDAC8 | |
| SCHEMBL28464025 | 0.75 | PYCR1 (0.53) | PYCR1TAAR1PTGESSIGMAR1RIPK1 | |
| SCHEMBL20871293 | 0.75 | PYCR1 (0.47) | PYCR1TAAR1PTGESSIGMAR1RIPK1 | |
| SCHEMBL608453 | 0.74 | TSHR (0.54) | PYCR1TAAR1MAOBHDAC1HDAC8 | |
| SCHEMBL2930128 | 0.74 | PYCR1 (0.53) | PYCR1TAAR1PTGESSIGMAR1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528132-B2 | immunodeficiencies, cancers, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease; indazolyl [1,2,4]triazine compounds | SCHERING CORPORATION (US) | 2009-05-05 | — | — | US | disclosed |
| US-20080004257-A1 | Kinase inhibitors | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004257-A1 | Kinase inhibitors | MAP3K1, MAP3K13, MAP3K6 | PYCR1 1580/4885TAAR1 2726/4885PTGES 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.